Lipomeg

Omega-3-Acid Ethyl Esters, the active ingredient in Lipomeg, is an omega‑3 fatty acid presented as an oral formulation for oral use. It is employed to modify lipid profiles, particularly to lower elevated triglyceride concentrations in adults, and may be used as an adjunct to diet and lifestyle measures for managing dyslipidaemia. Clinical experience shows it can reduce hepatic triglyceride synthesis and improve plasma lipid parameters.

GNH USA supplies Lipomeg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lipomeg, an omega‑3 fatty acid medication, is used to manage disorders of lipid metabolism.

- Hypertriglyceridemia: reduces elevated plasma triglyceride levels. - Familial hypertriglyceridemia: lowers triglycerides in genetically predisposed individuals. - Mixed dyslipidaemia: improves overall lipid profile when combined with other lipid‑lowering therapies.

Lipomeg is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Fish‑like aftertaste. - Nausea. - Diarrhoea. - Abdominal discomfort. - Flatulence. - Mild headache.

Serious or Rare Side Effects: - Pancreatitis. - Severe allergic reactions such as rash, angioedema, or anaphylaxis. - Elevated liver enzymes indicating hepatic injury. - Increased bleeding tendency, especially when combined with anticoagulants. - Acute hypersensitivity pulmonary events.

Before starting Lipomeg, consider the following precautions.

- Baseline triglyceride assessment: confirm elevated levels prior to therapy. - Liver function monitoring: periodic tests are recommended during long‑term use. - Anticoagulant therapy: be aware of potential increased bleeding risk. - Fish or shellfish allergy: evaluate for hypersensitivity before prescribing. - Pregnancy and lactation: safety not established; use only if benefits outweigh potential risks. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Lipomeg may interact with several medication classes.

Major Interactions (Avoid): - Warfarin or other anticoagulants: may potentiate bleeding. - Statins (especially high‑dose): increased risk of myopathy. - Cyclosporine: can raise omega‑3 plasma concentrations.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: possible additive blood‑pressure lowering effect. - Oral hypoglycaemic drugs: may affect glucose control. - Fibrates: monitor for combined triglyceride‑lowering effect and muscle toxicity.